tradingkey.logo

QuidelOrtho Corp

QDEL
查看詳細走勢圖
29.865USD
+0.915+3.16%
交易中 美東報價延遲15分鐘
2.03B總市值
虧損本益比TTM

QuidelOrtho Corp

29.865
+0.915+3.16%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.16%

5天

+3.70%

1月

+22.65%

6月

+6.55%

今年開始到現在

-32.96%

1年

-33.40%

查看詳細走勢圖

TradingKey QuidelOrtho Corp股票評分

單位: USD 更新時間: 2025-12-19

操作建議

QuidelOrtho Corp當前公司基本面數據相對謹慎,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名61/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價36.86。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

QuidelOrtho Corp評分

相關信息

行業排名
61 / 208
全市場排名
157 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 8 分析師
持有
評級
36.857
目標均價
+35.70%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

QuidelOrtho Corp亮點

亮點風險
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
估值合理
公司最新PE估值-1.66,處於3年歷史合理位
機構減倉
最新機構持股79.44M股,環比減少22.58%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉245.91K股

QuidelOrtho Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

QuidelOrtho Corp簡介

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
公司代碼QDEL
公司QuidelOrtho Corp
CEOBlaser (Brian J)
網址https://www.quidelortho.com/

常見問題

QuidelOrtho Corp(QDEL)的當前股價是多少?

QuidelOrtho Corp(QDEL)的當前股價是 29.865。

QuidelOrtho Corp 的股票代碼是什麼?

QuidelOrtho Corp的股票代碼是QDEL。

QuidelOrtho Corp股票的52週最高點是多少?

QuidelOrtho Corp股票的52週最高點是49.450。

QuidelOrtho Corp股票的52週最低點是多少?

QuidelOrtho Corp股票的52週最低點是19.500。

QuidelOrtho Corp的市值是多少?

QuidelOrtho Corp的市值是2.03B。

QuidelOrtho Corp的淨利潤是多少?

QuidelOrtho Corp的淨利潤為-2.05B。

現在QuidelOrtho Corp(QDEL)的股票是買入、持有還是賣出?

根據分析師評級,QuidelOrtho Corp(QDEL)的總體評級為持有,目標價格為36.857。

QuidelOrtho Corp(QDEL)股票的每股收益(EPS TTM)是多少

QuidelOrtho Corp(QDEL)股票的每股收益(EPS TTM)是-17.401。
KeyAI